A new study from the Keck School of Medicine of USC finds that two widely used blood tests for Alzheimer’s disease can accurately detect the condition in people with Down syndrome, a population at exceptionally high risk but often excluded from diagnostic research. In the first study of its kind, researchers showed that both the FDA-approved Lumipulse G p-tau217/β-Amyloid 1-42 test and the research-use PrecivityAD2 test reliably identified Alzheimer’s-related brain changes, with accuracy comparable to the general population. The findings also establish preliminary diagnostic thresholds tailored to individuals with Down syndrome and point to a more accessible, less invasive path for screening and diagnosis, with implications for clinical care and future trials.

Researchers at the Krieger Klein Alzheimer’s Research Center within the Rutgers Brain Health Institute, reviewed 25 years of data on dementia prevalence and risk factors in India. The findings, published in Alzheimer’s & Dementia, paves the way for the South Asian Middle Age Risk Tracking for brain Health (SAMARTH) study at Rutgers, the first research initiative in the United States dedicated to tracking the brain health of South Asian Americans and identifying modifiable risks and protective factors for Alzheimer’s Disease and related Dementias.

The misfolding of the amyloid beta protein is the strongest blood-based predictor for Alzheimer’s disease in the asymptomatic stage, indicating the risk of the disease years before it is clinically diagnosed and much earlier than the widely used plasma biomarker P-tau 217. This is the conclusion reached by a study led by Professor Klaus Gerwert (PRODI, Ruhr University Bochum, Germany). The research team analyzed blood samples from 17 years of 779 subjects in the population-based ESTHER cohort of the German Cancer Research Center (DKFZ) to compare the effectiveness of leading blood biomarkers throughout the entire course of Alzheimer’s disease. The study was published in the journal EMBO Molecular Medicine on July 16, 2026.

Results from a small clinical trial suggest it may be possible to reduce your risk of dementia by eating during fewer hours of the day. The pilot study, which involved a weight-loss program for older women with overweight or obesity, showed modest cognitive improvements in those who limited their daily eating window instead of just reducing their calorie intake.